Originally published by our sister publication Infectious Disease Special Edition
The results of an interim analysis from a second pivotal phase 3 clinical trial investigating the use of Gilead’s twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, found that it reduced HIV infections by 96% compared with background HIV incidence (bHIV).
There were two incident cases among 2,180 participants, corresponding to 99.9% of participants not acquiring HIV infection in the lenacapavir